Study: Arimidex superior to tamoxifen for early breast cancer

08/5/2005 | Guardian (London), The

A study in the journal Lancet says AstraZeneca's Arimidex proved superior to standard treatment with tamoxifen for women with early stages of breast cancer. In trials, women switched from tamoxifen to Arimidex, an aromatase inhibitor, for at least three years after after first treatment and immediately after surgery. The new drug costs eight times more than tamoxifen in the U.K., however.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA